Published • loading... • Updated
Novo Publishes Results From Study with Semaglutide as a Treatment for Fatty Liver
Summary by finans.dk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
The pharmaceutical company Novo presented results from two large observational studies at a congress on liver diseases on Friday evening. According to the company, the studies show a link between Wegovy and improved values in adults with the liver disease MASH.
On Friday, Novo published new data on Wegovy (semaglutide 2.4 mg) for the treatment of fatty liver disease Mash.
Novo has published data from studies of real-world outcomes of the drug semaglutide as a treatment for fatty liver at a conference in Denver on Friday.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
